Period-dependent survival benefit of percutaneous microwave ablation for hepatocellular carcinoma: 12-year real-world multicentric experience
| Autor: | Jie Yu, Zhi-Gang Cheng, Zhi-yu Han, Fang-Yi Liu, Rong-Qin Zheng, Wen Cheng, Qiang Wei, Song-Yuan Yu, Qin-ying Li, Guang-zhi He, Yan-chun Luo, Xiao-Ling Yu, Ping Liang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Liver Cancer (2022) |
| Druh dokumentu: | article |
| ISSN: | 2235-1795 1664-5553 00052213 |
| DOI: | 10.1159/000522134 |
| Popis: | Introduction: Although being a promising technique for hepatocellular carcinoma (HCC) treatment, the 10-year efficacies of microwave ablation (MWA) are unknown. Objective: To assess whether the advances of MWA for HCC translated into a real-world survival benefit. Methods: This retrospective study included 2,354 patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 to B from 5 hospitals, with at least 2 years of follow-up for all the patients. Recurrence and survival were analyzed using the Kaplan-Meier method with time-period stratification. Results: A total of 5,326 HCCs (mean diameter, 2.9 cm ± 1.2) underwent 4051 sessions of MWA with a median follow-up of 61.3 (ranging 0.6–169.5) months during three time-periods of 2007–2010, 2011–2014, and 2015–2018.Technical success was achieved in 5,194 (97.5%) tumors with significant improvement over time, especially for > 3.0 cm HCC (p 3.0 cm HCC and perivascular location were the risk factors for LTP. The median intra-hepatic metastasis time was 27.6 (95% CI 25.2–28.8) months, with 5- and 10-year occurence rate of 68.8% and 79.4%, respectively. The 5- and 10-year overall survival were 63.9% and 41.1%, respectively, and BCLC stage 0, A, B patients all with an observable survival improvement over time(p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|